Vascular Surgery OS
Start learning
← All domains
Procedure guide

Balloons — a practical guide for vascular trainees

A practical guide to angioplasty balloons for vascular trainees: plain, drug-coated, scoring and cutting balloons, sizing, inflation and troubleshooting.

Written October 1, 2026 · Mr Razhan K Ali

AT A GLANCE

A balloon catheter carries a folded balloon over a guidewire to a target vessel. Depending on its design, it can widen a narrowing, deliver an antiproliferative drug, modify calcium, mould an endograft or temporarily stop flow.[1,2,3,4,5]

Choose by what needs changing, then check size, pressure behaviour and compatibility. Failure to cross, failure to expand, recoil after deflation and later restenosis are different problems; they should not all prompt a larger balloon.[1,2]

Related guides: Endovascular guidewires · Endovascular catheters · Access, sheaths and closure devices.

DESIGN & FUNCTION

The parts and their jobs

The shaft transmits movement; the folded balloon sits near its distal end. Radiopaque markers guide positioning. The shoulders taper between balloon body and shaft and may extend beyond the markers, affecting an adjacent branch or narrower segment. Check the whole inflated footprint.[1,2]

The inflation lumen carries liquid into the balloon; a separate guidewire lumen tracks over the wire. In an over-the-wire (OTW) system, the wire traverses the full catheter. A rapid-exchange (RX/monorail) system has a short distal wire channel. OTW provides full-length support; RX simplifies exchanges but depends more on a sheath or guiding catheter near the target. A short wire suffices only when all planned exchanges permit it.[1,2,6]

What angioplasty changes

In an atherosclerotic artery, percutaneous transluminal angioplasty (PTA) enlarges the channel through plaque fracture and vessel-wall deformation—not simply plaque compression or removal. Dissection, separation within the wall, is part of this injury; its extent and effect on the lumen and flow determine its significance. Elastic recoil can reduce the gain immediately after deflation. Later tissue growth and remodelling can cause restenosis.[1,2,6]

Balloon angioplasty alone leaves no supporting scaffold. A drug coating targets the proliferative response to injury; it cannot hold open an artery that needs mechanical support.[2,3]

PROPERTIES & BEHAVIOUR

Compliance: how the diameter changes

Compliance is the change in balloon diameter as inflation pressure rises. A compliant balloon stretches substantially; a semi-compliant balloon enlarges within a more limited range; a non-compliant balloon changes relatively little across its working pressure range. Non-compliant does not mean zero growth or a rigid catheter shaft. Use the actual compliance chart.[1,2,7]

High pressure describes pressure tolerance, not compliance. Reinforcement can increase that tolerance but also increase the folded profile. More pressure capacity may help a resistant lesion; it does not make the artery more tolerant of dilatation.[1,2,8]

Nominal pressure and rated burst pressure

For PTA balloons, nominal pressure is the labelled pressure associated with the nominal balloon diameter. Rated burst pressure (RBP) is a statistically derived device limit based on bench testing—not a treatment target or the artery’s rupture threshold. A balloon can also fail within its pressure rating, for example against sharp calcium.[1,7,9]

Check the rating and diameter–pressure relationship for the exact balloon size. Use the pressure needed for the intended result within its instructions for use (IFU); do not exceed the labelled RBP.[7,9]

Delivery: reaching and crossing are different

PropertyMeaningWhy it matters
Crossing profileExternal size of the folded balloon region.Inflated diameter and shaft French size do not tell you the delivery profile.[1,7]
TrackabilityAbility to follow the wire through bends.Flexibility, friction and the access route affect delivery.[1,2]
PushabilityTransmission of forward movement to the distal catheter.Shaft bowing or system displacement can absorb the push.[1]
CrossabilityAbility to pass through the lesion itself.Tip design, folded profile and support matter; a wire crossing does not guarantee balloon passage.[1,2]

The profile changes after use. Deflation may leave folded “wings” rather than recreate the original tight wrap, making repeat crossing or withdrawal into the sheath harder. Inflation can also straighten a curved segment: watch the vessel and wire, not just the balloon.[1,2]

TYPES & EXAMPLES

Categories overlap: a drug-coated balloon (DCB) also has a compliance profile, pressure rating and delivery system. Examples identify designs, not interchangeable products.

Type / exampleDesign and useful roleMain limitation
Plain PTA — Sterling PTAMechanical dilatation; base Sterling also has a peripheral stent post-dilatation indication.[10]No scaffold or drug treatment; do not transfer permissions to Sterling SL.
High-pressure, low-compliance — Conquest 40Reinforced balloon for resistant lesions, including selected dialysis-access stenoses.[1,2,8]Higher pressure tolerance may cost delivery profile; vessel injury remains possible.
Scoring — AngioSculptExternal spiral nitinol elements concentrate force against resistant plaque or fibrotic tissue.[1,2,9]Added profile and device-specific sizing; scoring elements are not blades.
Cutting balloonLongitudinal blades incise resistant tissue, including selected recurrent or graft stenoses.[1,2]Blades add profile, rigidity and handling/injury hazards.
Drug-coated balloon (DCB)Paclitaxel or sirolimus delivery intended to reduce restenosis after an acceptable mechanical result.[3,11]No scaffold; evidence varies by platform, population and territory.
Intravascular lithotripsy (IVL) — Shockwave E8Balloon-mounted emitters generate acoustic pressure pulses that modify calcium and facilitate expansion.[4]Must reach the lesion. The cited E8 IFU limits use to lower-extremity peripheral arteries, excludes in-stent restenosis and mandates a device-specific pressure-and-pulse sequence.
Compliant occlusion / moulding — Coda and Coda LPTemporary large-vessel occlusion to control distal bleeding, or moulding compatible endograft sealing stents.[5]Syringe/volume-controlled. The 46 mm Coda must not be used in vessels below 24 mm or to dilate prostheses in iliac or other non-aortic vessels.[5]

CHOOSING THE TOOL

Identify the failure mechanism

It will not cross. Confirm the wire route and locate the resistance. Improve wire/sheath support or select a lower-profile balloon; staged predilatation may create a channel for the next device. If the system bows or moves instead of advancing, pushing harder is not the solution.[1,2]

It will not expand. A persistent waist marks resistance to expansion. If the ends expand while the middle stays pinched—dog-boning—higher pressure may stretch the neighbouring vessel more than the lesion. Recheck sizing and calcium. The next step may be a pressure-tolerant balloon, focal-force scoring/cutting or calcium modification, rather than a larger diameter.[1,2,4]

The lumen is inadequate after deflation. Distinguish recoil from an obstructing dissection. Selected dissections may respond to sustained low-pressure ballooning; persistent flow limitation or significant recoil/residual stenosis may need scaffolding or another reconstruction. More drug delivery does not solve a structural failure.[1,2]

The aim is to reduce later restenosis. Consider a DCB only after evaluating the clinical indication, lesion preparation and the evidence for that platform and territory. Better patency is not automatically a proven improvement in limb salvage, survival or quality of life.[3,12,13]

Drug balloons: keep the evidence specific

Paclitaxel-balloon trials suggest reductions in restenosis and repeat target-lesion treatment, but these do not establish corresponding gains in survival, limb salvage or quality of life.[14]

For infrainguinal treatment of intermittent claudication, the 2026 ESVS focused update limits paclitaxel-coated devices to selected restenosis cases after discussion of uncertain long-term safety and, at best, modest symptomatic benefit. It recommends endovascular revascularisation only for persistent lifestyle-limiting symptoms despite conservative therapy. This is narrower clinical advice than the MHRA’s February 2024 permission to consider these devices where indicated.[15,16] The update was prompted particularly by SWEDEPAD 2: no one-year disease-specific quality-of-life benefit and a five-year mortality signal, although mortality did not differ significantly over the full follow-up.[15,17]

For chronic limb-threatening ischaemia (CLTI), BASIL-3 found no significant amputation-free survival advantage for femoropopliteal DCB angioplasty over plain angioplasty, with optional bare-metal stenting in both balloon arms.[12] SWEDEPAD 1 analysed 2,355 patients with CLTI undergoing infrainguinal treatment and found no reduction in ipsilateral major amputation with paclitaxel-coated balloons or stents versus uncoated devices.[18] Neither result establishes equivalence or settles every drug-balloon indication.

SirPAD (2026) enrolled 1,252 patients with infrainguinal artery disease, not a CLTI-only cohort. Its one-year primary composite—unplanned major target-limb amputation or target-lesion revascularisation for critical limb ischaemia—occurred in 8.8% versus 15.0% after sirolimus-coated versus uncoated balloon angioplasty. It did not compare sirolimus with paclitaxel; do not extrapolate its result to every sirolimus platform or anatomical subgroup.[11]

SIZING & COMPATIBILITY

Size the vessel and the task

Measure the reference vessel diameter, not the stenotic channel or post-stenotic dilatation. Assess both ends and any taper; do not size a long segment from its proximal diameter alone. A conservatively sized initial balloon can help assess an uncertain or heavily calcified lesion.[1,2,3]

A fixed 1:1 or 1.1:1 ratio is not universal. Some specialty balloons require deliberate undersizing; others specify a different relationship to vessel diameter. Use the exact device’s sizing instructions.[1,4,9]

Cover the intended treatment length without unnecessary injury to adjacent vessel. For a DCB, cover the segment injured during preparation with the device-required margins: leaving injured but untreated edges is a geographic miss.[1,3]

Check reach, fit and permitted function

An illustrative 5 × 80 mm balloon on a 135 cm shaft describes nominal inflated diameter, treatment length and catheter reach—not the folded profile passing through the sheath. The sheath must accommodate both delivery and withdrawal.[1,2,7]

Check wire diameter, sheath/guide-catheter compatibility, usable shaft length and exchange-wire length separately. A longer contralateral or arm route changes reach requirements. Do not assume the wire lumen permits contrast injection or in-situ wire exchange: some IFUs prohibit one or both.[1,2,8,10]

For stent post-dilatation, check both devices’ instructions. Base Sterling permits this use.[10] AngioSculpt lacks clinical testing for post-dilatation of freshly deployed stents.[9] Stellarex must not be used to expand a stent.[3]

HANDLING PRINCIPLES

Prepare before obstructing flow

For conventional PTA balloons, use the specified liquid inflation medium, usually diluted contrast, and remove air from the balloon and connections. Do not inflate them with air or another gas. Viscous contrast can slow deflation. Prime as instructed rather than routinely pre-inflating and losing the low delivery profile.[1,2,9]

Protect the DCB coating: minimise handling; do not wipe, wet or immerse the coated balloon unless its IFU explicitly directs otherwise. Stellarex requires replacement after pre-use fluid contact with the coating.[3] Confirm planned anticoagulation and have the inflation system ready before positioning: even an uninflated balloon can obstruct a tight lesion.[1,10]

Position and inflate under control

Check the label: different diameters can look alike when folded. For angioplasty, confirm the intended wire course and distal position, centre the treatment segment and clear the sheath tip before inflation.[1,2]

For PTA and pressure-rated specialty balloons, use a pressure-monitored inflation device and fluoroscopy. Inflate progressively within the IFU. There is no universal inflation duration: lesion response, tolerance of flow interruption and device-specific drug-transfer or IVL instructions govern the sequence. Pain is a warning to assess, not an endpoint.[1,2,3,4,9]

Coda/Coda LP use a different method: syringe inflation using the prescribed medium and volume–diameter chart; their IFUs prohibit pressure inflation devices. Observe expansion under fluoroscopy and never exceed the model’s maximum volume. When moulding an endograft, keep the entire balloon within the prosthesis.[5]

Deflate, withdraw and judge the vessel

Confirm complete deflation under imaging before movement, using the specified aspiration/vacuum technique. Keep control of the wire and sheath during withdrawal; inspect the removed device for completeness.[1,4,9]

Compare lumen, flow and runoff with baseline. Look for dissection and extravasation; use additional views or intravascular ultrasound if uncertain. Loss of the waist is not the final endpoint. Preserve useful wire access until the result and any rescue requirement are clear.[1,2]

PITFALLS & TROUBLESHOOTING

ProblemPossible explanationChecks → response / stopping point
Balloon will not advanceTight lesion, poor support, kink or unsafe wire course.Confirm position and localise resistance. Improve support or reduce profile; do not force passage.[1,2,9]
Persistent waist / dog-boningResistant tissue, calcium or inappropriate sizing.Recheck dimensions and pressure limits; change the preparation strategy rather than chase the waist beyond the IFU.[1,2,9]
Balloon slips out of a short stenosisResistant circumferential or fibrotic tissue.Deflate before repositioning. Reassess length and support; a suitable longer or scoring balloon may help. Do not drag an inflated balloon back through the lesion.[1,9]
Pressure fallsThe waist may have yielded, or there may be a leak/failure.Correlate with balloon shape. Persistent loss, leakage or blood in inflation fluid suggests failure: stop, deflate and follow device-specific withdrawal instructions. Assess the vessel separately.[1,5,9]
Poor flow after deflationRecoil, obstructing dissection, thrombosis, embolisation or spasm.Compare the treated segment and runoff with baseline. Exclude mechanical obstruction and thromboembolism before assuming spasm.[1,2]
Extravasation, persistent severe pain or haemodynamic deteriorationPerforation/rupture; bleeding may be concealed.Retain useful access, image promptly and resuscitate. Use a vessel-appropriate balloon for local tamponade or proximal occlusion, following its IFU inflation method and limits. Prepare covered-stent or open repair for ongoing bleeding; a bare stent is not a reliable seal.[1,2,5]
Balloon will not deflate or withdrawSlow emptying, kink, incomplete deflation, folded wings or entrapment.Check the inflation pathway and maintain prescribed negative pressure. Do not pull an expanded or trapped balloon through the vessel, stent or sheath; stop and obtain a controlled retrieval plan.[1,2,9]

REMEMBER

  • Match the mechanism to the problem: crossing, expansion, recoil and restenosis are different tasks.
  • Compliance describes diameter change; RBP is a device limit, not the artery’s safety margin.
  • Match the inflation method to the device: pressure-rated PTA and volume-controlled Coda are not interchangeable.
  • Drug delivery does not replace an adequate mechanical result.
  • Deflate fully, preserve access and judge the vessel—not just the balloon.

REFERENCES

  1. Schneider PA. Endovascular Skills: Guidewire and Catheter Skills for Endovascular Surgery. 4th ed. CRC Press; 2020.
  2. Sidawy AN, Perler BA, eds. Rutherford’s Vascular Surgery and Endovascular Therapy. 10th ed. Elsevier; 2023.
  3. Philips. Stellarex 0.035-inch OTW Drug-Coated Angioplasty Balloon: Instructions for Use. US PMA labelling; IFU No. P011966-I, Rev 03/2022. Accessed 2 October 2026. IFU.
  4. Shockwave Medical. Shockwave E8 Peripheral Intravascular Lithotripsy Catheter: Instructions for Use. PN-71233 Rev C; document LBL 71005-C, 2024-08. European IFU served through the manufacturer’s index, accessed 2 October 2026. IFU.
  5. Cook Medical. Coda Balloon Catheter and Coda LP Balloon Catheters: Instructions for Use. T_CODA46-M_REV3; T_CODALP-M_REV2. Accessed 2 October 2026. Coda IFU; Coda LP IFU.
  6. Chaikof EL, Cambria RP, eds. Atlas of Vascular Surgery and Endovascular Therapy: Anatomy and Technique. Saunders; 2014.
  7. US Food and Drug Administration. Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters—Premarket Notification (510(k)) Submissions. 14 April 2023. Guidance.
  8. BD. Conquest 40 PTA Dilatation Catheters. UK product information and safety summary. Accessed 2 October 2026. Manufacturer information.
  9. Philips. AngioSculpt PTA Scoring Balloon Catheter: Instructions for Use. PN-3262-0001, Rev D, 03/20. IFU.
  10. Boston Scientific. Sterling PTA Balloon Dilatation Catheter: Indications, Safety and Warnings. Accessed 2 October 2026. Prescriptive information.
  11. Barco S, Engelberger RP, Held U, et al. Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease. N Engl J Med. 2026;395(6):561–570. doi:10.1056/NEJMoa2600360. Publication record.
  12. Bradbury AW, Hall JA, Popplewell MA, et al. Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial. BMJ. 2025;388:e080881. doi:10.1136/bmj-2024-080881. Original paper.
  13. Loftus I, Hinchliffe RJ, eds. Vascular and Endovascular Surgery: A Companion to Specialist Surgical Practice. 7th ed. Elsevier; 2024.
  14. Ma GW, Bernatchez J, Yarranton B, et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. 2026;8:CD011319. doi:10.1002/14651858.CD011319.pub3. Original review abstract.
  15. Nordanstig J, Hinchliffe R, Lejay A, Behrendt CA, et al. Editor’s Choice—Focused Update on Paclitaxel Coated Technologies, from the 2024 European Society for Vascular Surgery (ESVS) Guidelines on the Management of Asymptomatic Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg. 2026;71(6):923–927. doi:10.1016/j.ejvs.2026.04.037. Publication record.
  16. Medicines and Healthcare products Regulatory Agency. Paclitaxel coated devices used in the treatment of peripheral arterial disease: update to previous MHRA guidance. DSI/2024/001. 5 February 2024. MHRA alert.
  17. Nordanstig J, James S, Andersson M, et al. Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial. Lancet. 2025;406(10508):1115–1127. doi:10.1016/S0140-6736(25)01584-3. Original abstract.
  18. Falkenberg M, James S, Andersson M, et al. Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial. Lancet. 2025;406(10508):1103–1114. doi:10.1016/S0140-6736(25)01585-5. Original abstract.